Comprehensive analysis to identify transcriptomic signatures that positively or negatively correlate with clinical outcome of nivolumab monotherapy in patients with non-small cell lung carcinoma

Comprehensive analysis to identify transcriptomic signatures that positively or negatively correlate with clinical outcome of nivolumab monotherapy in patients with non-small cell lung carcinoma - CTSN study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027092

Enrollment

Registered

2017-04-21

Start date

2017-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subjects with histologically or cytologically-diagnosed NSCLC. 2) Subjects who are judged suitable for nivolumab monotherapy by investigators. 3) Recent fresh frozen tumor samples must be available for biomarker evaluation.

Exclusion criteria

Exclusion criteria: 1) Subjects with a condition requiring systemic treatment with either systemic corticosteroids or other immunosuppressive medications within 14 days of first nivolumab administration.

Design outcomes

Primary

Measure	Time frame
Identification of transcriptomic signatures that positively or negatively correlate with clinical outcome of nivolumab monotherapy	—

Countries

Japan

Contacts

Public ContactTomoiki Aiba

Sendai Kosei Hospital Respiratory medicine

tomowithkk@gmail.com81-22-222-6181

Outcome results